—Phase 2/3 platform trial sponsored by Cambridge University Hospitals NHS Foundation Trust——Experimental therapies with potential to prevent and treat complications […]
DUBLIN, Ireland, June 19, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization […]